BlueAllele is working to address the unmet therapeutic challenges in gene editing. Our approach is based on the core principles of innovating and developing the next level of safe and effective treatments for patients with genetic diseases.
Our team excels at correcting genes at the DNA level, and has core strengths to move the field forward and develop new therapies.
Our leaders bring a wide breadth of knowledge and experience, and a deep understanding of innovative genomic technology.
Joseph B. Saluri, J.D. Chief Executive Officer/Chairman of the Board
Joseph B. Saluri serves as BlueAllele’s Chairman of the Board and Chief Executive Officer.
Mr. Saluri has more than 24 years of leadership experience in biotechnology enterprises.
Mr. Saluri received his Juris Doctorate from Drake University Law School and his B.S.B.A. degree in investment finance from Drake University.
Nicholas Baltes, Ph.D. President/Chief Science Officer/Director
Dr. Nicholas Baltes serves as BlueAllele’s President and Chief Scientific Officer.
Dr. Baltes has more than 15 years of experience in research and 10 years of experience in gene editing, and is a registered patent agent.
Dr. Baltes received his Ph.D. in molecular biology from the University of Minnesota.
Jeremy S. Forest, J.D.Director
Jeremy S. Forest serves as a member of BlueAllele’s Board of Directors.
Mr. Forest has more than 15 years of experience in biotechnology and has held various management and leadership roles in startup companies and growth-stage ventures.
Mr. Forest received his Juris Doctorate from the University of New Hampshire School of Law and his M.S. degree in chemistry from the University of Hawaii.
Brian Wiley Strategic Advisor
Brian Wiley serves as a strategic advisor to BlueAllele.
Mr. Wiley has more than 25 years of experience in pharmaceuticals and biotechnology and has held various management and senior leadership roles in commercialization and business development.
Mr. Wiley received his bachelor’s degree in Marketing from the Pennsylvania State University.
Jack Henneman Strategic Advisor
Jack Henneman serves on BlueAllele’s strategic advisory committee.
Mr. Henneman has more than 25 years’ experience as an executive in the medical device and biotechnology industries.
Mr. Henneman is a graduate of Princeton University and the University of Michigan Law School.
BlueAllele's proprietary platform technologies in repair template design and optimization provide an opportunity to collaborate with partners who specialize in the development and commercialization of gene editing therapeutics. To learn more about partnering with BlueAllele get in touch.